Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of subcutaneous (under the skin) administration of VELCADE(R) (bortezomib). VELCADE(R) is indicated for the treatment of multiple myeloma, a type of blood cancer. Subcutaneous bortezomib has fewer side effects and offers greater convenience for patients, with similar efficacy compared to intravenous bortezomib. VELCADE(R) plays a central role in effectively managing multiple myeloma across different patient types and lines of therapy.[1,2] 

Abbott announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for HUMIRA (adalimumab) in adults with severe axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage. Upon final decision from the European Commission, HUMIRA will be the first and only approved medication available for non-radiographic axSpA patients (nr-axSpA).

Takeda Pharmaceutical Company Limited and AMAG Pharmaceuticals, Inc. today announced the granting of marketing authorization by the European Commission (EC) for ferumoxytol, a new intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). The marketing authorization follows a positive opinion issued on April 19, 2012, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). 

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc. , jointly announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product teduglutide (Revestive in Europe) as a once-daily treatment for adult patients with short bowel syndrome (SBS). 

GBI Research, a business intelligence provider, has released its latest research, 'Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar', which provides insights into bone metabolic disease therapeutics until 2018.